Q-omics provides the consensus-scored NAP1L5 profile across patient tissues and cancer cell-line models. NAP1L5 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, NAP1L5 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, NAP1L5 RNA expression shows 19,717 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight CESC, BLCA, and UVM as cancer lineages where NAP1L5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NAP1L5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NAP1L5 survival associations across molecular data types. NAP1L5 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NAP1L5 RNA expression–survival associations across cancer types. High NAP1L5 expression shows unfavorable associations in UVM and DLBC, but favorable associations in CESC, LGG, KIRC and LUAD. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify CESC as the clearest survival context for NAP1L5 RNA expression.
This table summarizes NAP1L5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for NAP1L5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NAP1L5 shows lower tumor expression in BLCA, KIRC, THCA, KIRP, LUAD and KICH. The BLCA box plot shows higher NAP1L5 RNA expression in normal versus tumor tissue (log2 FC = −1.425, t-test p < 0.001).
This table shows molecular features associated with NAP1L5 in patient tissues and cancer cell lines. In patient samples, NAP1L5 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, NAP1L5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
